➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
AstraZeneca
Johnson and Johnson
Express Scripts
Moodys

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VIRAMUNE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Viramune

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002166 ↗ An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease Completed Boehringer Ingelheim Phase 3 1969-12-31 To provide access to Viramune and to evaluate the tolerance and safety of Viramune in patients with progressive, symptomatic HIV disease who failed or are intolerant to currently approved treatment for HIV-1 infection and who are unable to participate in another Viramune controlled clinical trial and have a compelling need for anti-HIV treatment.
NCT00002194 ↗ An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4. Completed Boehringer Ingelheim Phase 1 1969-12-31 To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.
NCT00002368 ↗ The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs Completed Boehringer Ingelheim Phase 3 1969-12-31 To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Viramune

Condition Name

Condition Name for Viramune
Intervention Trials
HIV Infections 25
Hepatic Insufficiency 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Viramune
Intervention Trials
HIV Infections 27
Acquired Immunodeficiency Syndrome 6
Hepatic Insufficiency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Viramune

Trials by Country

Trials by Country for Viramune
Location Trials
United States 55
Brazil 4
Canada 4
United Kingdom 4
Argentina 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Viramune
Location Trials
California 6
New York 4
Rhode Island 4
Texas 3
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Viramune

Clinical Trial Phase

Clinical Trial Phase for Viramune
Clinical Trial Phase Trials
Phase 4 12
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Viramune
Clinical Trial Phase Trials
Completed 31
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Viramune

Sponsor Name

Sponsor Name for Viramune
Sponsor Trials
Boehringer Ingelheim 26
Abbott 2
Makerere University 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Viramune
Sponsor Trials
Industry 31
Other 13
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Merck
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.